Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInfectious Disease Physician in Hillsborough, NJ
NPI: 1023084928Primary Practice Location
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL - SOMERSET
110 Rehill Ave, Somerville, NJ
Primary Employer
ID Care LLC
idcare.com
HQ Phone
Get M.D. Ronald's Phone NumberMobile
Get M.D. Ronald's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNJ State Medical License
FL State Medical License
2020
NJ State Medical License
1983 - 2025
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Infectious Disease
Harvard School of Public Health
MHCM • Healthcare Leadership
2010 - 2012
Rutgers Health/Robert Wood Johnson Medical School
Residency • Internal Medicine
1982 - 1986
Rutgers Robert Wood Johnson Medical School
Medical School
Until 1982
Rensselaer Polytechnic Institute
B.S. • Cum Laude
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 103 | 173 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 99 | 207 |
| 3 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 49 | 154 |
| 4 | 36410Insertion of needle into vein, patient 3 years or older | 31 | 85 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs.
Authors: Kay Schwebke, Steven Schmitt, Russell Petrak
Publication Date: 2013-09-28
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.
Authors: Brunetti, Luigi, Diawara, Oumou, Tsai, Andrew, Firestein, Bonnie L, Nahass, Ronald G, Poiani, George, Schlesinger, Naomi
Journal: J Clin Med
Publication Date: 2020-09-14
Lead Sponsor: Arbutus Biopharma Corporation
Intervention / Treatment: DRUG: AB-729, DRUG: Peg-IFNα-2a
Lead Sponsor: ViiV Healthcare
Collaborators: Janssen, LP
Intervention / Treatment: DRUG: Cabotegravir Tablets, DRUG: Rilpivirine Tablets, DRUG: Cabotegravir Injectable Suspension (CAB LA), DRUG: Rilpivirine Injectable Suspension (RPV LA), DRUG: BIKTARVY Tablets (BIK)
Lead Sponsor: ViiV Healthcare
Collaborators: GlaxoSmithKline, PPD Development, LP
Intervention / Treatment: DRUG: DTG/3TC FDC, DRUG: CAR
